Stocktoria

BRISTOL MYERS SQUIBB CO BMY

NYSE · stock · Pharmaceutical Preparations · website · IPO 1980-03-17 · LEI

BRISTOL MYERS SQUIBB CO financials (annual)

Revenue
$19.43B $20.78B $22.56B $26.14B $42.52B $46.38B $46.16B $45.01B $48.30B $48.19B 2016201720182019202020212022202320242025
Net income
$4.46B $1.01B $4.92B $3.44B -$9.02B $6.99B $6.33B $8.03B -$8.95B $7.05B 2016201720182019202020212022202320242025
Free cash flow
$1.84B $4.22B $6.12B $7.37B $13.30B $15.23B $11.95B $12.65B $13.94B $12.85B 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$48.2B$48.3B$45.0B$46.2B$46.4B$42.5B$26.1B$22.6B$20.8B$19.4B
Gross profit$30.7B$18.1B$16.1B$14.7B$14.5B
R&D expense$10.0B$11.2B$9.3B$9.5B$10.2B$10.0B$6.1B$6.3B$6.5B$5.0B
SG&A expense$7.3B$8.4B$7.8B$7.8B$7.7B$7.7B$4.9B$4.6B$4.8B$5.0B
Interest expense$1.2B$1.2B$1.3B$1.4B$656.0M$183.0M$196.0M$167.0M
Income tax$2.3B$554.0M$400.0M$1.4B$1.1B$2.1B$1.5B$1.0B$4.2B$1.4B
Net income$7.1B-$8.9B$8.0B$6.3B$7.0B-$9.0B$3.4B$4.9B$1.0B$4.5B
EPS (diluted)$3.46$-4.41$3.86$2.95$3.12$-3.99$2.01$3.01$0.61$2.65
Operating cash flow$14.2B$15.2B$13.9B$13.1B$16.2B$14.1B$8.2B$7.1B$5.3B$3.1B
Free cash flow$12.8B$13.9B$12.7B$11.9B$15.2B$13.3B$7.4B$6.1B$4.2B$1.8B
Cash & equivalents$10.2B$10.3B$11.5B$9.1B$14.0B$14.5B$12.3B$6.9B$5.4B$4.2B
Inventory$2.7B$2.6B$2.7B$2.3B$2.1B$2.1B$4.3B$1.2B$1.2B$1.2B
Total assets$90.0B$92.6B$95.2B$96.8B$109.3B$118.5B$129.9B$35.0B$33.6B$33.7B
Total liabilities$71.5B$76.2B$65.7B$65.7B$73.3B$80.6B$78.2B$20.9B$21.7B$17.4B
Shareholders' equity$18.5B$16.4B$29.5B$31.1B$36.0B$37.9B$51.7B$14.1B$11.8B$16.3B

Growth · year-over-year · Revenue CAGR 10.6%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth-0.2%+7.3%-2.5%-0.5%+9.1%+62.6%+15.9%+8.6%+6.9%+17.3%
Net income growth-211.5%+26.8%-9.5%-362.1%-30.1%+388.6%-77.4%+184.8%
EPS growth-214.2%+30.8%-5.4%-298.5%-33.2%+393.4%-77.0%+184.9%
Free cash flow growth-7.9%+10.2%+5.9%-21.6%+14.5%+80.3%+20.6%+44.9%+129.0%+43.4%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.